Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis
Published in Semin Arthritis Rheum, 2024
To evaluate if initially starting glucocorticoid (GC) bridging leads to a higher probability of long-term GC and biological (b)DMARD use in rheumatoid arthritis (RA)-patients.
Recommended citation: van Ouwerkerk L, Bergstra SA, Maarseveen TD, Huizinga TWJ, Knevel R, Allaart CF. (2024) "Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis" Semin Arthritis Rheum. 2024 Feb;64:152305. doi: 10.1016/j.semarthrit.2023.152305. Epub 2023 Nov 10.
Recommended citation: van Ouwerkerk L, Bergstra SA, Maarseveen TD, Huizinga TWJ, Knevel R, Allaart CF. (2024) "Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis" Semin Arthritis Rheum. 2024 Feb;64:152305. doi: 10.1016/j.semarthrit.2023.152305. Epub 2023 Nov 10.
Download Paper